 3. Histologically or cytologically confirmed diagnosis of limited or extensive stage SCLC which failed one prior platinum-containing regimen and with a chemotherapy-free interval CTFI, time from the last dose of first-line chemotherapy to the occurrence of progressive disease 30 days. Small-cell carcinoma of unknown primary site with or without neuroendocrine features confirmed in histology tests performed on metastatic lesions are eligible, if Ki-67MIB-1 is expressed in 50 of tumor cells. 